Regulatory FDA Ties Amgen’s Rare Inflammatory Disease Drug to Eight Deaths, Dozens of Liver Injuries BioSpaceThe FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug's overall risk-benefit profile.RegulatoryImmunology & InflammationRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioSpace The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall risk-benefit profile. RegulatoryImmunology & InflammationRead full story Post navigation Previous: IO Shuts Down Following Regulatory RoadblocksNext: Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026